Lead-time bias in studies of cinacalcet prescriptions.
Observational studies have suggested a link between higher serum phosphate, calcium, parathyroid hormone levels, and cardiovascular mortality. The administration of cinacalcet has proven efficient in the treatment of secondary hyperparathyroidism among hemodialysis patients. In an observational study by Block et al., cinacalcet treatment is associated with a much improved all-cause and cardiovascular mortality. However, the results should be interpreted cautiously, as observational studies may be influenced by bias. This Commentary discusses the role of some common potential biases.
Evans
Marie
M
Division of Renal Medicine, Department of Clinical Science Intervention and Technology, Karolinska University Hospital, Huddinge, Stockholm, Sweden. Marie.Evans@ki.se
Fored
Carl Michael
CM
D015982:Bias; D002318:Cardiovascular Diseases / Q000401:mortality; D002423:Cause of Death; D000069449:Cinacalcet; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality; D009281:Naphthalenes / Q000627:therapeutic use*; D019370:Observation; D016896:Treatment Outcome
D009281:Naphthalenes; D000069449:Cinacalcet